The subject of this publication is the conclusion of contracts in accordance with Section 130a (8) SGB V for the following active substances / combinations of active substances in the context of a so-called open house procedure:

Botulinum toxin type A (M03AX21) without active substance strength 100 I.E.

Rosuvastatin and ezetimibe (C10BA06)

teriparatide (H05AA02)

rituximab (L01XC02)

trastuzumab (L01XC03)

All suitable and interested pharmaceutical companies or associations of pharmaceutical companies are offered the conclusion of a discount agreement in accordance with Section 130a (8) SGB V for the above-mentioned active ingredients / active ingredient combinations, subject to uniform contractual conditions and a standardized access procedure.

The earliest start of the contract is December 1, 2021. Based on this, the contract period is a maximum of 24 months.

All suitable and interested pharmaceutical companies or communities of pharmaceutical companies will be offered the conclusion of a discount agreement in accordance with Section 130a (8) of the SGB V for the aforementioned active substances/combinations of active ingredients, subject to uniform contract conditions and a uniform access procedure.

The earliest start of the contract is December 1, 2021. Based on this, the contract period is a maximum of 24 months.